Cost‐utility analysis of bevacizumab versus ranibizumab in neovascular age‐related macular degeneration using a Markov model (Q44680785)

5 December 2017

title

Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model (English)

1 reference

5 December 2017

Cost‐utility analysis of bevacizumab versus ranibizumab in neovascular age‐related macular degeneration using a Markov model (English)

1 reference

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01546.X

14 July 2024

1 reference

1 reference

0 references

Mark Bounthavong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846318

14 July 2024

Daniel Boggie

1 reference

5 December 2017

Jignesh J. Patel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846318

14 July 2024

Margaret A. S. Mendes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846318

14 July 2024

Melissa L. D. Christopher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846318

14 July 2024

Anthony P. Morreale

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846318

14 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20846318

14 July 2024

publication date

16 September 2010

1 reference

full work available at URL

5 December 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2753.2010.01546.x

1 reference

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01546.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2753.2010.01546.x

14 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01546.X

Journal of Evaluation in Clinical Practice

14 July 2024

published in

1 reference

5 December 2017

1 reference

5 December 2017

1 reference

5 December 2017

page(s)

247-255

1 reference

Prevalence of age-related macular degeneration in the United States

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Visual risk factors for hip fracture in older people

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Increased expression of angiogenic growth factors in age-related maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Utility values and age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

An introduction to Markov modelling for economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Handling uncertainty in cost-effectiveness models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01546.X

Effect of depression on vision function in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01546.X

Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes

14 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01546.X

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration

14 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01546.X

Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration

14 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01546.X

Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration

14 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01546.X

Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK

14 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01546.X

14 July 2024

Identifiers

1 reference

5 December 2017

1 reference